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Abstract
Aim: Chronic diseases often occur simultaneously and tend to be associated with adverse health outcomes, but
limited research has been undertaken to understand their role in lung cancer mortality. Therefore, this study aims
to describe the prevalence and patterns of having one (comorbidity) or ≥ 2 chronic diseases (multimorbidity)
among lung cancer patients in Spain, and to examine the association between comorbidity or multimorbidity and
short-term mortality risk at six months after cancer diagnosis.
Methods: In this population-based cohort study, data were drawn from two Spanish population-based cancer
registries, Girona and Granada, and electronic health records. We identified 1259 adult lung cancer patients,
diagnosed from 1st January 2011 to 31st December 2012. We identified the most common patterns of individual
comorbidities and their pairwise correlations. We used a flexible parametric modelling approach to assess the
overall short-term mortality risk 6 months after cancer diagnosis by levels of comorbidity after adjusting for age, sex,
smoking status, province of residence, surgery, cancer stage, histology, and body mass index.
Results: We found high prevalence of comorbidity in lung cancer patients, especially among the elderly, men,
those diagnosed with advanced-stage tumours, smokers, and obese patients. The most frequent comorbidities
were chronic obstructive pulmonary disease (36.6%), diabetes (20.7%) and heart failure (16.8%). The strongest
pairwise correlation was the combination of heart failure with renal disease (r = 0.20, p < 0.01), and heart failure with
diabetes (r = 0.16, p < 0.01). Patients with either one or two or more comorbidities had 40% higher overall mortality
risk than those without comorbidities (aHR for comorbidity: 1.4, 95%CI: 1.1–1.7; aHR for multimorbidity: 1.4, 95%CI:
1.1–1.8), when relevant confounding factors were considered.
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Conclusions: The presence of comorbid diseases, rather than the number of comorbidities, was associated with
increasing the risk of short-term lung cancer mortality in Spain. Comorbidity was a consistent and independent
predictor of mortality among lung cancer patients, six months after diagnosis. The most common comorbid
conditions were age-, obesity- and tobacco-related diseases. Our findings highlight the need to develop targeted
preventive interventions and more personalised clinical guidelines to address the needs of lung cancer patients
with one or more comorbidities in Spain.
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Background
Lung cancer is the most commonly diagnosed can-
cer worldwide and the leading cause of cancer
death, accounting for 18.4% of the total cancer
deaths in both men and women combined [1]. Dur-
ing 2020 the estimated number of new cases in
Spain was 29,188 and 22,930 estimated deaths, with
the European age-standardised mortality rate of 47.6
per 100,000 [2]. There is an increasing trend in lung
cancer incidence and mortality among women [3].
Over the last decade, Spain had the second highest
average increase in lung cancer incidence among
women after Brazil; and the largest increase in lung
cancer mortality than any other country in the
world [4].
Poor prognosis and increased mortality among lung
cancer patients are often associated with advanced
age and stage at diagnosis, identified in half of all pa-
tients [5, 6]. The elderly are more likely to be diag-
nosed with lung cancer and to experience
comorbidity (coexistence of an additional chronic dis-
ease) or multimorbidity (coexistence of more than
two chronic diseases) with a primary condition [7, 8].
Multimorbidity is more common among lung cancer
patients in comparison with patients diagnosed with
other types of cancer, such as breast, prostate or
colorectal cancer [9, 10]. However, the effects of mul-
timorbidity on lung cancer mortality have not been
adequately examined and available evidence is con-
flicting. Comorbidity and multimorbidity were inde-
pendent prognostic factors for lung cancer patients,
significantly related to an increasing mortality risk in
some studies, [11] but not in others [12–15]. Most of
the previous studies did not account for relevant life-
style and behavioural confounders, such as obesity or
smoking status, [16, 17] and none of them were con-
ducted in Spain. This study has two purposes: first, to
describe the prevalence of comorbidities and multi-
morbidity and their pattern of pairwise correlations in
lung cancer patients in Spain and, second, to examine
the association between multimorbidity and short-
term mortality at 6 months following the diagnosis of
lung cancer, adjusting for relevant clinical and life-
style confounders.
Materials and methods
This population-based cohort study included all primary
lung and bronchus cancer incident cases diagnosed from
1st January 2011 to 31st December 2012 in two Spanish
population-based cancer registries - Girona and Gran-
ada. The eligibility criteria included all adult patients
(aged 18 and over) diagnosed with primary lung and
bronchus malignant cancer, during 2011 and 2012 in Gi-
rona or Granada. We excluded patients younger than 18
years or those diagnosed with a secondary lung cancer.
The entry date was defined as the date of cancer diagno-
sis, while exit date was defined as the date of death or
the date at 6 months after their cancer diagnosis, which-
ever occurred first.
The data collection followed a detailed protocol from
the European High Resolution studies collaboration
(TRANSCAN-HIGHCARE project within the ERA-Net)
[13]. Lung cancer types and histological codes were clas-
sified according to the International Classification of
Diseases for Oncology, third edition (ICD-O-3) [18].
Lung cancer types were registered with codes C34.0,
C34.1, C34.2, C34.3, C34.8 and C34.9. The histological
subgroups were classified as 1) adenocarcinomas, 2)
small cell lung cancers, 3) squamous carcinomas, and 4)
unspecified and other subgroups (Supplementary
Table 1).
We recorded information on patients’ age, sex, smok-
ing status, province of residence, surgery, body mass
index (BMI), cancer stage at diagnosis (TNM staging
system, 7th edition), tumour histology, comorbidities,
and vital status.
Vital status was assessed at 6 months after cancer diag-
nosis and was ascertained based on information from
clinical records linked to the national death registry of
the Spanish National Statistics Institute. Short-term
mortality at six months was the outcome, and patients’
baseline comorbidity status at cancer diagnosis was the
main exposure. A priori confounders were age and sex.
Other relevant confounders were province of residence,
smoking status, performed surgery, stage at diagnosis,
tumour histology and BMI. Province of residence was
considered as a proxy measure for socio-economic
deprivation. Based on national figures of the household
average income from the National Institute of Statistics,
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Girona in the North of the country is more affluent than
Granada in Southern Spain [19]. BMI in kg/m2 was
categorised as healthy weight (< 24.9), overweight (25–
29.9), and obese (≥30 kg/m2) [20]. Comorbidities were
assessed retrospectively six months before cancer diag-
nosis using all the available information from patients’
electronic health records in primary care, outpatient,
and in-patient hospital information. Then, comorbidities
were identified using an algorithm based on the codes
from the International Classification of Diseases, 10th
Revision, and classified based on the Royal College of
Surgeons-modified Charlson score (RCS). The RCS re-
duces the number of comorbidities to 12, removes a cat-
egory (peptic ulcer disease), and groups diseases (e.g.,
diabetes mellitus codes with or without complications)
(Supplementary Table 2).
In this study comorbidity is defined as the occurrence
of a single medical conditions additional to an index dis-
ease, i.e. lung cancer [21]. Multimorbidity is defined as
the co-occurrence of multiple medical conditions (two
or more) in addition to the lung cancer diagnosis (the
index disease) [21]. Therefore, the final comorbidity
score represents a simple count of the total number of
comorbidities for each patient, without assigning any
weights, namely: no comorbidities (0), one comorbidity
(1), and two or more comorbidities, with (≥2) comorbid-
ities defined as multimorbidity [22].
The study proposal (CP17/00206) was approved by the
internal review board of the Andalusian School of Public
Health and the ethics committee from the Department
of Health of the Andalusian Regional Government
(study 0072-N-18). The data are held by the Regional
Government of Andalusia and the Andalusian Health
Department. This entire study and the research protocol
for involving human data was in accordance with the
guidelines of the Declaration of Helsinki.
Statistical analysis
Percentages were used to describe categorical variables,
and means and standard deviations for continuous vari-
ables. We described the ranked frequency of comorbidi-
ties and computed the pairwise correlation (i.e., between
pairs of the most common comorbidities) using the
Pearson correlation coefficient. In this way, we assessed
whether any of the medical conditions that lung cancer
patients are experiencing are correlated to one another,
and if so, how strong these correlations were. To assess
the association between short-term mortality and poten-
tial risk factors, in univariate analysis, we computed the
number of deaths and person-month at risk, the rates
and rates ratios at 6 months post-diagnosis and assessed
the presence of linear trends across levels of comorbidi-
ties, age, and BMI using the score test for trend. We
plotted the short-term cumulative incidence of death at
6 months by comorbidity and multimorbidity status,
based on the Aalen-Nelson estimator and assessed statis-
tical significance using the Log-rank test.
In multivariate analysis, to assess the risk of short-
term mortality by comorbidity status (including a single
comorbidity and multimorbidity), adjusted for relevant
confounders, we developed a survival analysis using a
flexible parametric modelling approach. The approach
allows for a better fit of the baseline hazard, imple-
mented through the smooth transformation of the base-
line hazard, using restricted cubic splines with two
internal knots and three degrees of freedom [23]. For
categorical variables we used the category at lower risk
in univariate analysis as a reference. We fitted seven dif-
ferent models including the variables one at each step to
assess confounding. From each model we derived the
hazard ratios (HR) and 95% confidence intervals (CI).
We performed a complete case analysis assuming a pat-
tern of completely missing at random.
To check the consistency of our main results against
the missing at random assumption, in sensitivity ana-
lysis, we developed a multiple imputation, using chained
equations based on a fully conditional specification [24].
We imputed BMI, tumour stage, performed surgery, and
smoking status, generating 50 imputed datasets. The re-
sults were combined using Rubin’s rules [25]. The model
specification for the multiple imputation included the
following variables: comorbidities, smoking status, prov-
ince, BMI, age at diagnosis, sex, tumour stage and hist-
ology; and, as auxiliary variables, the Nelson-Aalen
cumulative hazard. Furthermore, we assessed the dose-
response effect of the number of comorbidities (i.e., 0, 1,
2, and + 3) among lung cancer patients on short-term
cancer mortality.
Data were analysed using Stata v.16.1 (StataCorp, Col-
lege Station, Texas, U.S.) [26].
Results
A total of 1259 lung cancer cases (83.4% male) were in-
cluded in the analysis (Supplementary Table 3). Average
age was 68.4 years (SD: 11.7). Over half of males (51.9%)
and a third of females (35.4%) were above 70 years old.
The majority were ever-smokers (87.1%), with 41.3%
current smokers and 45.7% former smokers. More than
half of patients (58.0%) were above the healthy weight
(average BMI: 26.3 kg/m2, SD: 4.8). Surgery was per-
formed in 16.6% of the cases. Over half of patients were
diagnosed with metastatic tumours (54.7%), with more
metastatic tumours diagnosed in Granada (57.8%) than
Girona (49.9%, p < 0.01). A third of patients (33.4%) had
multimorbidity and 28.0% a single comorbidity.
Half of 80+ year-olds had multimorbidity, but 58.9% of
below 60-year-olds had no comorbidities (p < 0.001,
Table 1). Males had higher multimorbidity prevalence
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Table 1 Vital status at six-months, sociodemographic characteristics, smoking status, province of residence, body mass index, cancer
surgery, histology, and TNM stage by multimorbidity status among lung cancer patients diagnosed between 2011 and 2012, in two
population-based Spanish cancer registries: Girona and Granada (n = 1259 lung cancer patients and 581 deaths at six-months after
cancer diagnosis)
Variable Royal College of Surgeons-modified Charlson score
No comorbidity One comorbidity Two or more comorbidities p-value
N (%) N (%) N (%)
Vital status at 6months 0.001
Alive 290 (42.8) 189 (27.9) 199 (29.4)
Dead 196 (33.7) 164 (28.2) 221 (38.0)
Age at diagnosis, years < 0.001
< 60 179 (58.9) 77 (25.3) 48 (15.8)
60–69 132 (39.4) 111 (33.1) 92 (27.5)
70–79 110 (28.4) 113 (29.2) 164 (42.4)
≥ 80 65 (27.9) 52 (22.3) 116 (49.8)
Sex < 0.001
Male 355 (33.8) 321 (30.6) 374 (35.6)
Female 131 (62.7) 32 (15.3) 46 (22.0)
Smoking status < 0.001
Current smoker 187 (41.3) 144 (31.8) 122 (26.9)
Previous smoker 126 (25.2) 153 (30.5) 222 (44.3)
Never smoked 65 (45.8) 37 (26.1) 40 (28.2)
Province 0.019
Girona 216 (43.3) 133 (26.7) 150 (30.1)
Granada 270 (35.5) 220 (29.0) 270 (35.5)
Body Mass Index (kg/m2) < 0.001
Healthy weight (< 25.0) 142 (45.8) 92 (29.7) 76 (24.5)
Overweight (25.0–29.9) 99 (35.9) 90 (32.6) 87 (31.5)
Obese (≥30) 33 (21.9) 45 (29.8) 73 (48.3)
Surgery 0.163
Yes 81 (40.1) 63 (31.2) 58 (28.7)
No 362 (35.8) 289 (28.6) 361 (35.7)
Histology < 0.001
ADE 176 (46.1) 101 (26.4) 105 (27.5)
Others 134 (35.5) 99 (26.2) 145 (38.4)
SCLC 73 (44.2) 44 (26.7) 48 (29.1)
SQUA 103 (30.8) 109 (32.6) 122 (36.5)
TNM stage 0.014
I 0 (0.0) 1 (20.0) 4 (80.0)
II 67 (35.1) 61 (31.9) 63 (33.0)
III 107 (30.7) 106 (30.4) 136 (39.0)
IV 267 (40.5) 183 (27.8) 209 (31.7)
Histology: ADE: adenocarcinoma; SCLC: small cell lung cancer; SQUA: Squamous carcinoma;
Others: non-small cell lung cancer, large cell lung cancer, neuroendocrine lung cancer,
and unspecified lung cancer. P-values based on Chi-square tests
Missing values: BMI n (%) = 522 (41.5), Performance status n (%) = 229 (18.2),
Smoking status n (%) = 163 (13.0), TNM stage n (%) = 55 (4.4), Surgery n (%) = 45 (3.6)
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than females (35.7% vs. 22.0%, respectively p < 0.001).
Former smokers had the highest multimorbidity preva-
lence (44.4% vs. 26.9% never-smokers, p < 0.001). Obese
patients had double prevalence figures than those with
healthy weight (48.3% vs. 24.5%, respectively p < 0.001).
A third of patients with squamous carcinoma, and”
Other” histology subgroup, including unspecified carcin-
omas, had multimorbidity (36.5% vs. 38.4%, p < 0.001).
The most prevalent comorbidities were chronic ob-
structive pulmonary disease (COPD) (36.6%), diabetes
(20.7%) and heart failure (16.8%). The most frequent
pairwise combination was COPD and diabetes (8.7%),
followed by COPD and heart failure (7.9%) (Supplemen-
tary Table 4). Figure 1 shows the pattern of pairwise cor-
relations between the most common comorbidities
(Fig. 1A) and the two-side significance value set at 0.01
(Fig. 1B). The highest pairwise correlation was between
heart failure and renal disease (r = 0.20, p < 0.01),
followed by heart failure and diabetes (r = 0.16, p < 0.01).
Among 5391 person-month at risk, 581 people died
before six-months of follow-up i.e., 196 patients without
comorbidity, 164 with a single comorbidity, and 228
with multimorbidity (Table 2). The overall observed
short-term mortality rate was 10.8 per 100 person-
month at risk (95%CI: 9.9–11.7). Figure 2 shows that the
cumulative incidence of death at six-months was in-
creasing across the two levels of comorbidity, with the
highest risk among those with multimorbidity (log-rank
test p = 0.002). In univariate analysis, patients with mul-
timorbidity also had the highest overall short-term mor-
tality rate (i.e., MR: 13.0; 95% CI: 11.4–14.8 per 100
person-month) and mortality rate ratio (i.e., MRR: 1.4;
95% CI: 1.2–1.7) compared with patients with one or no
comorbidity.
Results from the multiple imputation model (Table 3:
model 8) were consistent with the complete case analysis
(Table 3: model 7). After adjusting for all confounders in
model 7, patients with comorbidity or multimorbidity
showed a 40 and 50% increased short-term mortality risk
in comparison with patients without comorbidity (ad-
justed Hazard Ratio [aHR]: 1.4 and 95% CI: 1.0–2.0 and
1.1–2.2, respectively). Not having surgery increased the
mortality risk six times (aHR: 6.2; 95% CI: 3.0–13.1). Pa-
tients with metastatic cancer had over two times higher
mortality than non-metastatic patients (aHR: 2.5; 95%
CI: 1.8–3.5). Patients over 80 years old had two times
higher mortality risk than those below 60 years of age
(aHR: 2.1; 95% CI: 1.3–3.4). Current smokers had 50%
higher mortality risk than never-smokers (aHR: 2.1; 95%
CI: 1.1–3.9). Patients from Granada had higher mortality
risk than those from Girona (aHR: 1.8; 95% CI: 1.4–2.4).
In sensitivity analysis the number of comorbidities did
not show a dose-response effect, i.e., when we analysed
lung cancer patients with a single comorbidity, two co-
morbid medical conditions, or three and more comorbid
conditions (supplementary Table 5).
Discussion
This population-based cohort study revealed that both a
single comorbidity and multimorbidity were consistent
and independent prognostic factors of short-term mor-
tality among lung cancer patients in Spain. Six months
Fig. 1 Correlogram of comorbidities among Lung cancer patients in Granada and Girona, Spain, diagnosed during 2011–2012 (n = 1260). A)
Pearson’s correlation coefficient for the pairwise correlations between the most common comorbidities; B) Pearson’s correlation two-side
significance value set at p < 0.01 for the pairwise correlations between the most common comorbidities
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after diagnosis, lung cancer patients with one or multiple
comorbidities had a 40% higher risk of all-cause mortal-
ity than those without comorbidities, after adjusting for
age, sex, histology, smoking status, province of residence,
performed surgery, BMI, and tumour stage. We found
high prevalence of comorbidity in lung cancer patients,
especially among the elderly; men; those diagnosed with
advanced-stage; smokers and obese patients.
We confirmed findings from other population-based
studies that found comorbidity to be prognostically
Table 2 Short–term (six–months) mortality rates and rates ratios by comorbidity status, sex, age, smoking status, province of
residence, BMI, surgery, cancer histology, and TNM stage among lung cancer patients diagnosed between 2010 and 2012, in two
population-based Spanish cancer registries: Girona and Granada (n = 1259 lung cancer patients and 581 deaths at six–month after
cancer diagnosis)
Variables Deaths / PM MR per 100 PM (95% CI) MRR
(95% CI)
P–value
RCS-modified Charlson score < 0.001*
No comorbidity 196 / 2166 9.0 (7.9–10.4) Ref.
One comorbidity 164 / 1526 10.7 (9.2–12.5) 1.2 (1.0–1.5)
Two or more comorbidities 221 / 1698 13.0 (11.4–14.8) 1.4 (1.2–1.7)
Sex 0.009
Male 502 / 4435 11.3 (10.4–12.4) Ref.
Female 79 / 956 8.3 (6.6–10.3) 1.4 (1.1–1.7)
Age at diagnosis (years) < 0.001*
< 60 108 / 1470 7.3 (6.1–8.9) Ref.
60–69 131 / 1569 8.3 (7.0–9.9) 1.1 (0.9–1.5)
70–79 181 / 1630 11.1 (9.6–12.8) 1.5 (1.2–1.9)
≥ 80 161 / 721 22.3 (19.1–26.1) 3.0 (2.4–3.9)
Smoking status at diagnosis 0.176
Never smoked 53 / 687 7.7 (5.9–10.1) Ref.
Previous smoker 222 / 2199 10.1 (8.9–11.5) 1.3 (1.0–1.8)
Current smoker 204 / 2002 10.2 (8.9–11.7) 1.3 (1.0–1.8)
Province < 0.001
Girona 189 / 2274 8.3 (7.2–9.6) Ref.
Granada 392 / 3116 12.6 (11.4–13.9) 1.5 (1.3–1.8)
Body Mass Index (kg/m2) 0.101*
Healthy weight (< 25.0) 96 / 1551 6.2 (5.1–7.6) Ref.
Overweight (25.0–29.9) 82 / 1427 5.7 (4.6–7.1) 0.9 (0.7–1.2)
Obese (≥30) 40 / 796 5.0 (3.7–6.9) 0.8 (0.6–1.2)
Surgery < 0.001
Yes 8 / 1216 0.7 (0.3–1.3) Ref.
No 541 / 4084 13.2 (12.2–14.4) 20.1 (10.0–40.5)
Histology 0.002
ADE 152 / 1800 8.4 (7.2–9.9) Ref.
Others 247 / 1215 20.3 (17.9–23.0) 2.4 (2.0–2.9)
SCLC 66 / 715 9.2 (7.3–11.8) 1.1 (0.8–1.5)
SQUA 116 / 1654 7.0 (5.8–8.4) 0.8 (0.7–1.1)
TNM stage < 0.001
I–III (No-metastasis) 143 / 2810 5.1 (4.3–6.0) Ref.
IV (Metastasis) 398 / 2474 16.1 (14.6–17.8) 3.2 (2.6–3.8)
* Test for trend p-value
CI: Confidence Interval; MR: Mortality Rate; MRR: Mortality Rate Ratio; PM: Person–month;
Histology: ADE: adenocarcinoma; SCLC: small cell lung cancer; SQUA: Squamous carcinoma; Others: non-small cell lung cancer, large cell lung cancer,
neuroendocrine lung cancer, and unspecified lung cancer
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relevant and associated with lung cancer mortality, after
controlling for relevant confounders, such as age, sex, or
stage at diagnosis [27–30]. This association was not rep-
licated in other, mainly smaller single-centre studies
[12–14]. The discrepancy may be because the latter were
single-centre studies that failed to take into account rele-
vant confounders, [12–14] or dated population-based
studies where common comorbidities, such as cardiovas-
cular diseases, were underreported [15]. Sandfeld-
Paulsen et al. [31] argue that the association between co-
morbidity and lung cancer mortality can be detected
only by using register-based data, including reliable in-
formation on all cancer patients in a defined region and
time period. However, the main disadvantage of
population-based studies is that they often fail to con-
sider relevant lifestyle and behavioural factors, such as
smoking status. To the best of our knowledge, our study
is unique in revealing that this association remains stable
after controlling for relevant lifestyle factors, such as
obesity and smoking status. Furthermore, the estimated
mortality risk in our study was in line with a review of
studies, which concluded that mortality in lung cancer
patients was between 1.1 to 1.5 times higher for patients
with than those without comorbidity [17].
We did not find that the mortality risk was higher with
an increasing number of chronic conditions, since the
presence of either comorbidity or multimorbidity had
comparable impact on lung cancer mortality. Results
from previous studies are conflicting; while some studies
found this gradient, [29, 32] others did not [14, 33]. This
may be partly attributable to patients’ clinical
characteristics. Studies including early stage lung cancer
patients were more likely to report that multimorbidity
contributed to increased mortality, while those including
patients with advanced-stage cancer did not find multi-
morbidity had any important prognostic value [9]. For
patients with early-stage lung cancer or any potentially
curable cancer, such as early-stage breast or prostate
cancer, the presence and number of comorbid condi-
tions may be more likely to predict their mortality risk
[9, 10]. On the other hand, patients diagnosed with
advanced-stage disease or more aggressive cancers with
poor prognosis, such as lung cancer, are more likely to
die from their cancer regardless of other concomitant
disease.
We found that the impact of comorbidity on lung can-
cer mortality was independent of cancer stage or pa-
tients’ age, but these factors may be prognostically
complementary to comorbidity status [30]. Elderly pa-
tients with metastasis had a two times higher mortality
risk than younger patients without metastasis, confirm-
ing findings from previous studies [27, 34]. We argue
that advanced age is a prognostic factor of mortality, be-
cause the elderly tend to receive less active lung cancer
treatment, including less chemotherapy, radiotherapy or
surgery than younger patients [35].
Although surgical resection remains the main and
most effective lung cancer treatment, it is only indicated
in early stage tumours [36]. Our study included 16% of
patients with stage I and II tumours, with the matching
16% of performed surgeries. The probability of success-
ful surgery is further reduced with advanced age and the
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Fig. 2 Cumulative probability of death during the first 6 months after lung cancer diagnosis by comorbidity status
Niksic et al. BMC Cancer         (2021) 21:1048 Page 7 of 12
Table 3 Short-term (six-months) comorbidity and multimorbidity mortality risk adjusted for sex, age, province of residence, smoking
status, cancer surgery, histology, TNM stage, and BMI among lung cancer patients in Girona and Granada, Spain in 2011 (n = 1259

















N (sample size) 1259 1259 1259 1096 1092 1084 706 1259
RCS-modified Charlson score
No comorbidity Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
One comorbidity 1.1 (0.9–1.3) 1.1 (0.9–1.4) 1.1 (0.9–1.4) 1.4 (1.1–1.7) 1.4 (1.1–1.8) 1.5 (1.2–1.9) 1.4 (1.0–2.0) 1.4 (1.1–1.7)
Two or more comorbidities 1.1 (0.9–1.4) 1.1 (0.9–1.4) 1.1 (0.9–1.4) 1.5 (1.1–1.9) 1.4 (1.1–1.8) 1.5 (1.2–1.9) 1.5 (1.1–2.2) 1.4 (1.1–1.8)
Sex
Female Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
Male 0.8 (0.7–1.1) 0.8 (0.6–1.0) 0.8 (0.6–1.0) 0.9 (0.6–1.2) 0.9 (0.6–1.2) 0.8 (0.6–1.1) 0.8 (0.5–1.2) 0.8 (0.6–1.2)
Age at diagnosis in years
< 60 Ref. Ref. Ref. Ref. Ref. Ref. Ref. Ref.
60–69 1.1 (0.8–1.4) 1.1 (0.8–1.4) 1.1 (0.8–1.4) 1.0 (0.8–1.4) 1.0 (0.8–1.4) 0.9 (0.7–1.3) 1.0 (0.7–1.5) 1.0 (0.8–1.3)
70–79 1.4 (1.1–1.8) 1.4 (1.1–1.8) 1.4 (1.1–1.8) 1.3 (1.0–1.7) 1.2 (0.9–1.6) 1.3 (1.0–1.7) 1.1 (0.7–1.6) 1.4 (1.1–1.9)
≥ 80 2.7 (2.1–3.5) 2.1 (1.6–2.8) 2.1 (1.6–2.7) 2.0 (1.5–2.7) 1.7 (1.2–2.3) 1.9 (1.4–2.6) 2.1 (1.3–3.4) 2.1 (1.6–2.8)
Histology
ADE Ref. Ref. Ref. Ref. Ref. Ref. Ref.
Others 1.9 (1.5–2.4) 1.9 (1.5–2.3) 1.7 (1.3–2.1) 1.6 (1.3–2.0) 1.8 (1.4–2.2) 1.5 (1.0–2.2) 1.8 (1.4–2.2)
SCLC 1.1 (0.8–1.5) 1.1 (0.8–1.4) 0.9 (0.7–1.3) 0.7 (0.5–1.0) 0.8 (0.6–1.1) 0.7 (0.4–1.0) 0.9 (0.6–1.2)
SQUA 0.7 (0.6–1.0) 0.8 (0.6–1.0) 0.7 (0.5–0.9) 0.8 (0.6–1.0) 1.0 (0.7–1.3) 0.9 (0.6–1.3) 1.0 (0.7–1.2)
Province
Girona Ref. Ref. Ref. Ref. Ref. Ref.
Granada 1.3 (1.1–1.6) 1.5 (1.3–1.9) 1.5 (1.2–1.8) 1.4 (1.2–1.7) 1.8 (1.4–2.4) 1.4 (1.1–1.7)
Smoking status at diagnosis
Never smoked Ref. Ref. Ref. Ref. Ref.
Previous smoker 1.4 (1.0–2.1) 1.5 (1.1–2.2) 1.5 (1.0–2.1) 2.0 (1.0–3.8) 1.6 (1.1–2.3)
Current smoker 1.7 (1.2–2.5) 1.7 (1.2–2.4) 1.6 (1.1–2.3) 2.1 (1.1–3.9) 1.5 (1.0–2.1)
Surgery
Yes Ref. Ref. Ref. Ref.
No 16.0 (8.0–32.3) 9.4 (4.6–19.1) 6.2 (3.0–13.1) 10.2 (5.0–20.8)
TNM stage
I-III (No-metastasis) Ref. Ref. Ref.
IV (Metastasis) 2.4 (1.9–3.0) 2.5 (1.8–3.5) 2.3 (1.9–2.8)
Body Mass Index (kg/m2)
< 24.9 Ref. Ref.
25.0–29.9 1.0 (0.7–1.3) 0.9 (0.6–1.2)
≥ 30 0.8 (0.6–1.2) 0.7 (0.5–1.1)
HR: hazard ratio; CI: confidence interval
Histology: ADE: adenocarcinoma; SCLC: small cell lung cancer; SQUA: Squamous carcinoma; Others: non-small cell lung cancer, large cell lung cancer,
neuroendocrine lung cancer, and unspecified lung cancer
Model 1: adjusted for sex and age;
Model 2: adjusted for sex, age and histology;
Model 3: adjusted for sex, age, histology and province of residence;
Model 4: adjusted for sex, age, histology, province of residence and smoking status;
Model 5: adjusted for sex, age, histology, province of residence, smoking status, and cancer surgery;
Model 6: adjusted for sex, age, histology, province of residence, smoking status, cancer surgery, and TNM stage;
Model 7: adjusted for sex, age, histology, province of residence, smoking status, cancer surgery, TNM stage, and BMI;
Model 8: model 7 with imputed BMI, TNM stage, surgery, and smoking status
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presence of comorbidities, mainly due to the expected
higher incidence of postoperative complications [15, 37].
Evidence suggests that between 24 and 70% of cancer
patients with comorbidity are not treated according to
guidelines [17]. We did not have reliable information
whether surgery was performed with curative intent.
Even if a small number of patients had surgery, we
found that it was highly protective of mortality risk.
Therefore, we argue that in most cases surgery was per-
formed with curative intent.
Sex did not affect the short-term mortality, when rele-
vant confounders were considered, although women had
lower mortality risk than men. Consistent with our find-
ings, other studies found that lung cancer mortality
trends were higher among women than men, but mor-
tality rates were still higher among Spanish men [38, 39].
An increasing trend of tobacco use among women and
the decreasing trend among men may contribute to this
[38]. Granada had consistently higher overall short-term
mortality than the wealthier Northern region of Girona,
which confirms that social inequalities may play an im-
portant role in lung cancer mortality [40].
Comorbidity remains more prevalent among patients
diagnosed with lung than other cancer types [10, 17, 41,
42]. A possible explanation may be found in lifestyle fac-
tors contributing to lung cancer, especially smoking and
obesity - the main risk factors for many chronic condi-
tions [17, 29]. An estimated 26–81% of lung cancer pa-
tients have at least one other chronic medical condition
i.e., comorbidity, consistent with our results [17]. A large
population-based cohort study, done in Canada, found
that almost all (91%) people diagnosed with different
types of cancer had other chronic medica conditions;
and almost a quarter (23%) of them had five or more co-
occurring conditions [42]. They found that lung cancer
patients had among the highest prevalence of multimor-
bidity than patients diagnosed with 15 other types of
cancer, and early death most commonly occurred among
the lung cancer patients. Different from Koné and
Scharf, however, is that we did not find that mortality is
increasing with higher number of chronic medical con-
ditions. This may be because instead of focusing on pa-
tients diagnosed with a range of different cancers, we
analysed lung cancer patients only, who have worse
prognosis and higher mortality than most other cancer
patients. Moreover, we adjusted our analysis for lifestyle
factors, such as smoking and obesity status, and clinical
factors, such as tumour histology and surgery, which
may contribute to this discrepancy.
We confirmed high smoking prevalence among lung
cancer patients in Spain [43]. Smoking contributes to
over 80% of lung cancers in high-income countries,
and, therefore, preventive strategies require strict to-
bacco control [1]. The most common comorbid
conditions were age- and tobacco-related illnesses,
such as respiratory (e.g., COPD) and cardiovascular
(e.g., heart failure) diseases, consistent with earlier
studies [15, 36]. Significant overlap occurs between
symptoms of these diseases and lung cancer, including
cough, dyspnea and chest tightness [44]. Another com-
mon comorbidity, unrelated to tobacco use, was dia-
betes, sharing the same risk factors with lung cancer,
such as age, diet and smoking [36, 45]. Our findings
highlight the most prevalent comorbidities among lung
cancer patients and the pattern of correlations between
the most common comorbidities. This highlights the
need for further research to better understand the rela-
tionships between these chronic conditions and how
they might interact. For example, are patients with co-
morbidities more likely to be diagnosed with lung can-
cer early because of their frequent medical
appointments, or they are more likely to have delayed
diagnosis because the symptoms of their comorbid dis-
eases are masking early signs of lung cancer? Future
studies should also explore whether these common co-
morbidities have an additive or a multiplicative effect
on lung cancer mortality.
The majority of patients in our study had advanced-
stage cancer, probably because early lung cancer symp-
toms are hard to recognise or they overlap with other
diseases, such as COPD, causing delays in diagnosis [44].
A national lung cancer awareness campaign was intro-
duced in England, following reports that early symp-
toms, such as “persistent cough or hoarseness” were
least frequently recognised by the public, especially
among the elderly, males and the socioeconomically dis-
advantaged people, who also reported most barriers to
seeking medical help [46]. The campaign achieved an in-
crease in the number of medical appointments and diag-
nostic tests, as well as a shift towards an early-stage lung
cancer diagnosis, when outcomes are more favourable
[47, 48]. There are currently no national campaigns in
Spain aimed at raising awareness about early symptoms
of lung cancer and encouraging early diagnosis. Introdu-
cing such campaigns may have long-term benefits for
lung cancer patients in Spain.
This is the first high-resolution study addressing the
effect of comorbidity on short-term overall mortality
among lung cancer patients in Spain. Accessing patients’
EHRs allowed us to enrich data from two population-
based cancer registries addressing lifestyle factors, such
as smoking and BMI, not often assessed in population-
based studies. We used multiple imputations to address
missing values, performing analyses with both observed
and imputed values. We used a relatively reliable comor-
bidity measure, reducing the possibility to misclassify the
comorbid conditions, but some residual bias is possible
due to unmeasured comorbidities.
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This study has limitations. First, data were collected
during 2011 and 2012, because the data collection
was part of the European High Resolution studies and
this was the most complete population cohort avail-
able. Although this must be considered when inter-
preting the results, it is unlikely that the distribution
of lung cancer incidence and main comorbidities
would be significantly different in the more recent
years. Second, we were unable to perform analysis in-
cluding the malnourished patients (i.e., BMI category
< 18.5 kg/m2) due to a small number of cases in this
category (N = 22). Future studies should explore the
role of malnutrition, especially among the elderly, as
it may contribute to adverse health outcomes, such as
a more advanced neoplastic disease or COPD. Third,
the RCS is a simple measurement, created to compare
comorbidity in patients planned for a surgical inter-
vention. Using this score can simplify the data collec-
tion from digital medical records, but some
conditions may be excluded, such as psychiatric dis-
eases, other neoplasms, hypertension, non-COPD
chronic respiratory diseases or autoimmune diseases.
Therefore, the presence of different comorbidities
may be underrepresented, and its impact on short-
term lung cancer mortality may be even higher than
we estimated in this study. Fourth, the prevalence of
comorbidities might not be applicable to other re-
gions or countries. However, the clustering of chronic
conditions is likely to have a synergistic effect on
health outcomes, regardless of geographical coordi-
nates. Finally, we did not have information on other
lifestyle factors, such as exercise, diet, alcohol con-
sumption, the onset and duration of smoking or de-
tailed socio-demographic descriptors, such as patients’
income. Future studies should investigate these factors
and include data from all population-based cancer
registries in Spain.
Conclusion
The presence of comorbid diseases, rather than the
number of comorbidities, is associated with an in-
creasing risk of short-term lung cancer mortality in
Spain. Developing national or local campaigns fo-
cused on rising symptom awareness may encourage
early lung cancer diagnosis. Additional efforts are re-
quired to introduce targeted preventive interventions,
such as more rigorous smoking cessation interven-
tions, which may decrease the incidence of lung can-
cers combined with other comorbid diseases. The
development of more personalised healthcare guide-
lines is needed to address the complex treatment
management of lung cancer patients with comorbid-
ity in Spain.
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